This study evaluates targeted liposomes loaded with the α-particle generator 225Ac to
selectively kill prostate-specific membrane antigen (PSMA)–expressing cells with the aim to …

This study aims to evaluate the effect on killing efficacy of the intracellular trafficking patterns
of α-particle emitters by using different radionuclide carriers in the setting of targeted …

A theoretical drawback to α-particle therapy with 213Bi is the short range of the particle track
coupled with the short half-life of the radionuclide, thereby potentially limiting effective …

Disseminated, metastatic cancer is frequently incurable. Targeted α-particle emitters hold
great promise as therapeutic agents for disseminated disease. 225Ac is a radionuclide …

Prostate specific membrane antigen (PSMA) is a marker for diagnosis and targeted delivery
of therapeutics to advanced/metastasized prostate cancer. We report a liposome-based …

α-Particle emitters targeting the prostate-specific membrane antigen (PSMA) proved
effective in treating patients with prostate cancer who were unresponsive to the …

Promising biochemical responses to 225Ac-prostate-specific membrane antigen (PSMA)
617, even in patients who are refractory to β-particle radiation, illustrate the potential of …

Purpose To further improve tumour targeting and delivery of imaging agents by long-
circulating liposomes via the coupling of the anti-cancer monoclonal antibody 2C5 with …

Absorbed dose profiles within tumor spheroids simulating avascular micrometastases have
been calculated for a variety of liposome-and antibody-radionuclide combinations to assess …

Prostate-specific membrane antigen (PSMA) is a membrane-bound antigen expressed on
the surface of prostate cancer cells, and this paper describes the use of an antibody against …